Roundup Lawsuit: Latest Settlement News, Court Rulings, and Case Updates

The Roundup lawsuit continues to generate significant legal activity heading into the fall of 2026, with a proposed multibillion-dollar settlement, a key appellate ruling, and a landmark U.S. Supreme Court decision all converging within the span of a few months. For the tens of thousands of people who have filed a Roundup lawsuit against Bayer and its subsidiary Monsanto, these developments could shape how, when, and whether they receive compensation. This article breaks down where the Roundup lawsuit stands today, what has actually been decided, and what remains uncertain.

Because this litigation involves ongoing court proceedings, it is important to distinguish between allegations, proposed settlement terms, and final court decisions. Nothing in this article should be read as a guarantee of eligibility, approval, or payout amounts.

Roundup Lawsuit: Latest Legal Developments

As of late August 2026, the Roundup lawsuit landscape includes three major threads that every plaintiff, potential claimant, and observer should understand:

1. Bayer’s proposed $7.25 billion settlement of Roundup cancer claims, filed in Missouri state court, remains pending court approval.
2. On August 27, 2026, the Eighth Circuit Court of Appeals dismissed a challenge brought by objecting plaintiffs who sought to block the settlement from proceeding in state court.
3. On June 25, 2026, the U.S. Supreme Court ruled in Monsanto Co. v. Durnell that federal pesticide law preempts certain state law failure to warn claims tied to Roundup.

Each of these developments affects the Roundup lawsuit differently, and each is discussed in detail below. It is worth repeating upfront: the $7.25 billion settlement has not received final court approval. A hearing to consider approval is currently scheduled for September 14, 2026, and objections from some plaintiffs remain unresolved.

What Is the Roundup Lawsuit About?

The Roundup lawsuit refers to a large body of product liability litigation brought against Monsanto, the manufacturer of the widely used glyphosate based herbicide Roundup, and its parent company Bayer, which acquired Monsanto in 2018 for approximately $63 billion. Plaintiffs in the Roundup lawsuit allege that exposure to Roundup, particularly through repeated or prolonged use, is associated with the development of non Hodgkin lymphoma and other blood cancers.

The Roundup cancer lawsuit is not a single case but rather thousands of individual lawsuits filed by farmers, landscapers, groundskeepers, agricultural workers, and home gardeners across the country. Many of these cases have been consolidated for pretrial purposes in a federal multidistrict litigation known as In re: Roundup Products Liability Litigation, MDL No. 2741, which is overseen by U.S. District Judge Vincent Chhabria in the Northern District of California. Thousands of additional cases have proceeded separately in state courts, most notably in Missouri and California.

Why Are People Suing Bayer and Monsanto?

At the center of the Roundup lawsuit is a straightforward legal question: did Monsanto adequately warn consumers and workers about potential health risks associated with Roundup use? Plaintiffs in the Monsanto lawsuit generally argue that the company:

• Knew or should have known about a possible link between glyphosate exposure and certain cancers
• Failed to include adequate warnings on Roundup product labels
• Continued to market Roundup as safe despite mounting scientific debate

Bayer disputes these allegations. The company maintains that decades of regulatory review, including by the U.S. Environmental Protection Agency (EPA), have concluded that glyphosate is unlikely to cause cancer in humans when used as directed. Bayer has consistently stated that it stands behind the safety of Roundup and has pursued settlements primarily to reduce ongoing litigation costs and uncertainty, not as an admission of liability.

Roundup and Alleged Cancer Risks

It is important to be precise about what has and has not been scientifically or legally established. In 2015, the International Agency for Research on Cancer (IARC), a branch of the World Health Organization, classified glyphosate as “probably carcinogenic to humans” based on limited evidence in humans and sufficient evidence in animal studies. This classification became a central piece of evidence cited by plaintiffs in Roundup cancer lawsuits.

However, other regulatory bodies have reached different conclusions. The EPA has repeatedly evaluated glyphosate and has consistently found that it is not likely to cause cancer in humans when used according to label instructions, a position shared by several international regulatory agencies. This scientific disagreement has been a recurring theme throughout the glyphosate litigation, and courts have generally allowed juries to weigh competing evidence rather than resolving the scientific question as a matter of law.

In short, the claim that Roundup causes cancer remains a disputed allegation at the heart of the litigation, not an established scientific or legal fact. Bayer continues to reject that characterization, while plaintiffs continue to allege a causal association supported by select scientific studies and jury findings in earlier trials.

The Proposed $7.25 Billion Settlement

In February 2026, Bayer announced that its Monsanto unit had reached a proposed agreement worth up to $7.25 billion to resolve a large share of pending and certain future Roundup lawsuits. The proposed nationwide class settlement was filed in Missouri state court and is designed to establish a long term claims program funded through capped annual payments over a period of up to 21 years, rather than a single lump sum payout.

According to reporting at the time of the announcement, Bayer was facing Roundup lawsuit claims from approximately 65,000 plaintiffs in state and federal courts. The proposed settlement framework reportedly would apply to individuals diagnosed with non Hodgkin lymphoma following Roundup exposure before the settlement’s cutoff date, with compensation determined through a tiered structure based on factors such as age and extent of exposure.

It is critical to understand that this proposed settlement is not the same as a final, court approved settlement. The $7.25 billion figure represents Bayer’s proposed framework, not a distributed or guaranteed fund. Final approval requires a Missouri state court judge to review the settlement’s fairness, adequacy, and reasonableness at a formal hearing, following an opportunity for class members to object or opt out.

Latest Court Ruling and Settlement Developments

The path toward final approval of the Roundup settlement has not been simple. The Missouri Circuit Court originally scheduled a fairness hearing for earlier in 2026, but that hearing has been rescheduled multiple times. Most recently, on August 6, 2026, the Missouri Circuit Court granted a joint motion by Monsanto and class counsel to reschedule the final approval hearing to September 14, 2026.

Adding further complexity, a group of objecting plaintiffs, represented by attorney Ashley Keller, has argued that a state court lacks the authority to fast track a nationwide resolution of Roundup lawsuits, and that such matters should instead fall under the jurisdiction of the federal judge already overseeing the consolidated federal MDL. These objectors attempted to challenge the settlement’s procedural path through the federal appellate system.

On August 27, 2026, the Eighth Circuit Court of Appeals dismissed this challenge, declining to block the case from proceeding in Missouri state court. This followed an earlier ruling in June 2026 by a federal district court judge, who determined that the class settlement case, known as King v. Monsanto, should be remanded back to Missouri state court rather than heard federally. The Eighth Circuit’s decision does not itself approve the settlement. It simply allows the Missouri state court process, including the September 14, 2026 fairness hearing, to move forward. The objecting plaintiffs’ attorney has indicated an intention to continue contesting the settlement directly before the state court.

This distinction matters for anyone following Roundup lawsuit updates: the Eighth Circuit ruling addressed a procedural jurisdictional question, not the underlying fairness or adequacy of the $7.25 billion proposal itself.

What the Supreme Court Ruling Means

Separate from the settlement proceedings, the U.S. Supreme Court issued a significant decision affecting Roundup litigation more broadly. On June 25, 2026, the Court ruled 7 to 2 in Monsanto Co. v. Durnell that the Federal Insecticide, Fungicide, and Rodenticide Act, commonly known as FIFRA, expressly preempts certain state law failure to warn claims against pesticide manufacturers.

The case arose after a Missouri jury awarded John Durnell approximately $1.25 million after finding that Monsanto failed to adequately warn him about cancer risks associated with decades of Roundup use. Writing for the majority, Justice Brett Kavanaugh explained that because the EPA has repeatedly evaluated glyphosate and concluded that a cancer warning is not required on Roundup labels, a state law claim demanding such a warning would impose a labeling requirement “in addition to” or “different from” federal requirements, which FIFRA does not permit. The Court reversed the verdict in Monsanto’s favor. Justice Ketanji Brown Jackson, joined by Justice Neil Gorsuch, dissented.

The practical effect of this ruling on the broader Roundup lawsuit landscape is significant but not absolute. Legal analysts note that Durnell forecloses failure to warn claims premised specifically on the argument that Roundup’s label should have included a cancer warning the EPA declined to require. However, the ruling does not eliminate all avenues for plaintiffs. Claims based on design defect, manufacturing defect, negligent testing, fraud, or other theories not directly tied to labeling requirements may still proceed, depending on the facts of each case and applicable state law.

Following the Durnell decision, Bayer has argued in federal court, including before Judge Chhabria overseeing the MDL, that many remaining claims are effectively repackaged failure to warn claims that should also be dismissed. Plaintiffs’ attorneys dispute this characterization, arguing that negligence and design defect theories raise distinct legal questions that Durnell does not resolve. This disagreement remains unsettled and is likely to be litigated further in the federal Roundup multidistrict litigation.

Current Federal and State Litigation

Understanding the full scope of Roundup litigation requires looking at both the federal and state tracks separately.

• Federal litigation: The federal Roundup multidistrict litigation, MDL No. 2741, remains active before Judge Chhabria in the Northern District of California. Estimates of the number of pending federal cases have varied somewhat depending on the source and reporting date, with figures ranging from roughly 3,900 to more than 4,500 cases in 2026. This litigation continues to address bellwether trials, evidentiary disputes, and the aftermath of the Durnell ruling.
• State litigation: A substantially larger number of Roundup lawsuits are pending in state courts across the country, with some industry estimates placing the total number of active state and federal claims at approximately 60,000 or more as of mid to late 2026. Missouri, California, and other states have hosted individual jury trials in past years, some resulting in substantial verdicts for plaintiffs and others favoring Monsanto.
• Prior settlements: Bayer has stated that it has already resolved a substantial share of earlier Roundup claims, with cumulative settlement and verdict payments reported at approximately $10 to $11 billion across nearly 100,000 claims prior to the current $7.25 billion proposal. Those earlier resolutions did not cover future claims, which is part of why Bayer pursued the new nationwide settlement framework.

Given the number of moving pieces, sources sometimes report slightly different figures for pending case counts or total settlement payouts. These discrepancies generally reflect different reporting dates and methodologies rather than contradictory facts, and readers should treat exact figures as approximate and subject to change as litigation continues.

Who May Be Affected by the Settlement?

Not every person who has filed a Roundup lawsuit or who believes they were exposed to Roundup will automatically be included in the proposed settlement. Eligibility, if the settlement is ultimately approved, will depend on the specific terms set by the court, including factors such as:

• Diagnosis of non Hodgkin lymphoma or other qualifying conditions
• Timing of Roundup exposure and diagnosis relative to settlement cutoff dates
• Whether an individual is part of the certified settlement class or has opted out
• Documentation of exposure and medical history

Individuals who have already settled claims individually, opted out of the class, or fall outside the settlement’s defined class period may not be covered by these terms. Anyone who believes they may have a Roundup cancer claim, whether or not they are currently part of a lawsuit, is generally advised to consult with a qualified attorney to evaluate their individual circumstances rather than assume automatic inclusion in any pending settlement.

What Could Happen Next?

Several outcomes remain possible as the Roundup lawsuit moves toward the September 14, 2026 hearing:

• The Missouri state court could approve the settlement as proposed, potentially with modifications.
• The court could reject or delay approval if it finds the settlement terms inadequate or the objection process incomplete.
• Objecting plaintiffs may continue to challenge the settlement’s fairness directly before the state court, even after losing their jurisdictional appeal at the Eighth Circuit.
• The federal MDL could see further motions from Bayer seeking dismissal of claims based on the Durnell preemption ruling, with plaintiffs’ attorneys opposing broad application of that decision.
• Additional individual trials could continue in both federal and state courts for plaintiffs who are not part of, or who opt out of, any approved class settlement.

No outcome is guaranteed, and this article does not predict how the Missouri court will rule at the September hearing or how the federal litigation will ultimately be resolved.

Key Takeaways

• The Roundup lawsuit remains active on multiple fronts, including a proposed $7.25 billion settlement, ongoing federal MDL litigation, and thousands of individual state court cases.
• The proposed settlement, announced in February 2026, has not been finally approved. A fairness hearing is scheduled for September 14, 2026, in Missouri state court.
• On August 27, 2026, the Eighth Circuit Court of Appeals dismissed a challenge by objecting plaintiffs, allowing the state court settlement process to proceed, but this ruling did not decide the settlement’s merits.
• The Supreme Court’s June 25, 2026 ruling in Monsanto Co. v. Durnell found that federal pesticide law preempts certain failure to warn claims, though other legal theories may remain available to plaintiffs.
• Eligibility for any approved settlement will depend on specific court determined criteria, and not all Roundup claimants will automatically be included.
• Individuals with questions about a potential Roundup claim or settlement eligibility should consult a qualified attorney, since litigation developments continue to evolve.

Frequently Asked Questions